Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2021; 27(23): 3317-3326
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3317
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3317
Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?
Atsushi Nishida, Kyohei Nishino, Keitaro Sakai, Yuji Owaki, Yoshika Noda, Hirotsugu Imaeda, Department of Gastroenterology and Hepatology, Nagahama City Hospital, Nagahama 5268580, Shiga, Japan
Author contributions: Nishida A wrote the paper; Nishino K, Sakai K, Owaki Y, Noda Y, and Imaeda H contributed critical revision of the manuscript.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Atsushi Nishida, MD, PhD, Chief Doctor, Department of Gastroen
Received: March 17, 2021
Peer-review started: March 17, 2021
First decision: April 17, 2021
Revised: April 23, 2021
Accepted: May 7, 2021
Article in press: May 7, 2021
Published online: June 21, 2021
Processing time: 93 Days and 2.2 Hours
Peer-review started: March 17, 2021
First decision: April 17, 2021
Revised: April 23, 2021
Accepted: May 7, 2021
Article in press: May 7, 2021
Published online: June 21, 2021
Processing time: 93 Days and 2.2 Hours
Core Tip
Core Tip: In this review, we discuss the gut microbiota in inflammatory bowel disease and gut microbiota-derived metabolites, especially short chain fatty acids. The anti-inflammatory function of short chain fatty acids on the mucosal immune system in the gastrointestinal tract is also discussed. In addition, we review the efficacy of probiotics on inflammatory bowel disease and the current clinical trials on the effectiveness of fecal microbiota transplantation on inflammatory bowel disease.